UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,700 shares, an increase of 2,250.0% from the December 15th total of 200 shares. Based on an average daily trading volume, of 13,700 shares, the short-interest ratio is currently 0.3 days.

UCB Stock Down 0.3 %

OTCMKTS:UCBJY traded down $0.26 during mid-day trading on Tuesday, hitting $97.63. 9,673 shares of the company’s stock traded hands, compared to its average volume of 10,209. UCB has a twelve month low of $44.26 and a twelve month high of $100.66. The company has a fifty day moving average of $96.71 and a 200 day moving average of $90.58. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.